Allurion Technologies Inc Q3 2025 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Joshua Jennings - DD Cohen - Analyst : Hi Good morning. Thanks for taking the questions. Shanton, congrats on the progress with the FDA process and just thinking about that progress. Wanted to start with just how you're taking the learnings from the international strategy to focus on accounts that that offer comprehensive obesity care, and how that's informing potential US commercial strategy and any updates just on how, learning on plans to attack the US market once approvals in hand.

Question: Joshua Jennings - DD Cohen - Analyst : Thanks for that and just thinking about the international. Push and the strategic pivot, the solid 3rd quarter revenue results and help us just think about the progression from here just as we're thinking about modelling 4Q in 2026, just how international revenues could shape up over the next 12 to 24 months.

Question: Joshua Jennings - DD Cohen - Analyst : Appreciate that. And just lastly, you're talking about you around smart capsules as potentially transforming into a platform technology with drug delivery. Any other, details to share just in terms of timelines of the development program and then any other elements of the pipeline that you want to highlight in terms of the development projects for the platform. Thank you.